Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid

Lancet

Volumn 353, Issue 9167, 1999, Pages 1843-1847

  Vernon, Andrew ^a   Burman, William ^b   Benator, Debra ^c   Khan, Awal ^a   Bozeman, Lorna ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS;

EID: 0033614603     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)11467-8     Document Type: Article

References (42)

1. Dickinson JM, Mitchcison DA. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 1987; 68: 113-18.
2. DhillonJ, Dickinson JM, Guy JA, Ng TK, Mitchison DA. Activity of two long-acting rifamycins, rifapentine and FCE22807, in experimental murine tuberculosis. Tuber Lung Dis 1992; 73: 116-23.
3. Ji B, Truffot-Pernot C, Lacroix C, et al. Effectiveness of rifampin, rifabutin and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993; 148: 1541-46.
4. He GJ, and Shanghai Municipal Coordinating Group of Investigation on the Efficacy of Rifapentine. A comparative study of rifapentine treatment and three years follow-up on initial pulmonary tuberculosis. Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih 1993; 16: 73-76.
5. Biya Y, Lizhen Z, Fengying Z. National cooperative group on the clinical study of rifapentine: a clinical comparative study of Chinese-made rifapentine on chemotherapy of tuberculosis (follow-up results after three years). China Antibiotic 1992; 17: 313-22.
6. Arioli V, Berti M, Carniti G, Randisi E, Rossi E, Scotti R. Antibacterial activity of DL473, a new semisynthetic rifamycin derivative. J Antibiot (Tokyo) 1981; 34: 1026-32.
7. Moore M, Onorato IM, McCray E, Castro KG. Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA 1997; 278: 833-37.
8. Heifets LB (ed). Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton: CRC Press, 21-22.
9. American Thoracic Society. Treatment of tuberculosis infection in adults and children. Am J Resp Crit Care Med 1994; 149: 1359-74.
10. Yates JW, Chalmers B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980; 45: 2220-24.
11. 1 Cave MD, Eisenach KD, Templeton G, et al. Stability of DNA fingerprinting pattern produced with IS6 1 10 in strains of Mycobacterium tuberculosis. J Clin Microbiol 1994; 32: 262-66.
12. Miller LP, Crawford JT, Shinnick TM. The rpoß gene of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994; 38: 805-11.
13. Hong Kong Chest Service/British Medical Research Council. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981; i: 171-74.
14. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179-84.
15. Burman WJ, Cohn DL, Rietmeijer CA. Judson JA, Sbarbaro JA, Reves RR. Noncompliance with directly observed therapy for tuberculosis: epidemiology and effect on the outcome of treatment. Chest 1997; 111: 1168-73.
16. Ridzon R, Whitney CG, McKenna MT, et al. Risk factors for rifampicin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998; 157: 1881-84.
17. Munsiff SS, Joseph S, Ebrahimzadeh A, Freiden TR. Rifampin-monoresistant tuberculosis in New York City, 1 993-1 994. Clin Inf Dis 1997; 25: 1465-67.
18. Miller LP, Blumberg HM, Shinnick TM. A molecular and epidemiologic study of rifampicin-resistant strains of Mycobacterium tuberculosis at an inner city hospital, 199 1-1994. Abstract from Lancet Conference: The Challenge of Tuberculosis, September 14-15, 1995; Washington DC.
19. 9 Mason GR, Nita A. Emergence of MDR during standard therapy in AIDS. Am J Respir Crit Care Med 1997; 155:A221 (abstr).
20. Bishai WR, Graham NM, Harrington S, et al. Rifampicin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. N Engl J Med 1996; 334: 1573-76.
21. Hoechst Marion Roussel. Package insert for priftin (rifapentine) in USA. Gaithersburg MD, 1998.
22. Tarn CM, Chan SL, Lam CW, et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Am J Respir Crit Care Med 1998; 157: 1726-33.
23. Grosset J, Lounis N, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Ji B. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am J Respir Crit Care Med 1998; 157: 1436-40.
24. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970; 17: 28-106.
25. East African/British Medical Research Council. Controlled clinical trial of five short-course (4 months) chemotherapy regimens in pulmonary tuberculosis. Am Rev Respir Dis 1 98 1; 123: 165-70.
26. Tanzania/British Medical Research Council. Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1985; 131: 727-31.
27. Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Resp Dis 1993; 148: 1292-97.
28. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970; 20: 810-14.
29. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Appl Microbiol 1970; 20: 810-14.
30. Mitchison DA. Development of rifapentine: the way ahead. Int J Tuberc Lung Dis 1998; 8: 612-15.
31. Cavenaghi R. Rifampicin raw material characteristics and their effect on bioavailability. Bull Int Union Tuberc Lung Dis 1989; 64: 36-37.
32. Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996; 30: 919-25.
33. Sahai J, Gallicane K, Swick L, et al. Reduced plasma concentrations of antituberculous drugs in patients with HIV infection. Ann Intern Med 1997; 127: 289-93.
34. Acocella G, Nonis A, Perna G, Patane E, Gialdroni-Grassi G, Grassi C. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. Am Rev Respir Dis 1988; 138: 886-90.
35. Parkin DP, Vandenplas S, Botha FJH, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Grit Care Med 1997; 155: 1717-22.
36. Tuberculosis Chemotherapy Centre, Madras. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull WHO 1970; 43: 143-206.
37. Singapore Tuberculosis Service/British Medical Research Council. Isoniazid for pulmonary tuberculosis in Singapore: the results up to 30 months. Am Rev Respir Dis 1977; 116: 807-20.
38. Ellard GA. The potential clinical significance of isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis. Tubercle 1984; 5: 211-27.
39. Trapnell CB, Narang PK, Li R, Lavelle JP. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Int Med 1996; 124: 573-76.
40. Pilheu JA, Galati MR, Yunis AS, et al. Pharmacokinetic interaction of ketoconazole, isoniazid, and rifampicin. Medicina 1989; 49: 43-47.
41. Combs DL, O'Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann Intern Med 1990; 112: 397-406.
42. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998; 47: 1-58.